Gastroenterology diagnosis and treatment guidelines for irritable bowel syndrome: Treatment;Guías clínicas de diagnóstico y tratamiento en gastroenterología del síndrome de intestino irritable: Tratamiento

Revista de Gastroenterologia de Mexico

Volumn 74, Issue 1, 2009, Pages 63-70

  Schmulson, Max J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; IRRITABLE COLON; PRACTICE GUIDELINE;

HUMANS; IRRITABLE BOWEL SYNDROME; PRACTICE GUIDELINES AS TOPIC;

EID: 84863653548     PISSN: 03750906     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med 1992;116:1009-16.
2. Thomas KB. General practice consultations: is there any point in being positive? Br Med J (Clin Res Ed) 1987;294:1200-2 (Pubitemid 17070676)
3. Schmulson M, Ortiz-Garrido OM, Hinojosa C, Arcila D. A single session of reassurance can acutely improve the self-perception of impairment in patients with IBS. J Psychosom Res 2006;61:461-7. (Pubitemid 44441438)
4. Halpert A, Dalton CB, Palsson O et al. Patient Educational Media Preferences for Information About Irritable Bowel Syndrome (IBS). Dig Dis Sci 2008;53:3184-90.
5. Halpert A, Dalton CB, Palsson O, Morris C, Hu Y, Bangdiwala S et al. What patients know about irritable bowel syndrome (IBS) and what they would like to know. National Survey on Patient Educational Needs in IBS and development and validation of the Patient Educational Needs Questionnaire (PEQ). Am J Gastroenterol 2007;102:1972-82.
6. Tillisch K, Chang L. Diagnosis and treatment of irritable bowel syndrome: state of art. Curr Gastroentorol Rep 2005;7:249-56. (Pubitemid 41223336)
7. Valenzuela J, Alvarado J, Cohen H et al. Un consenso latinoamericano sobre el síndrome del intestino irritable [Latin-American consensus document on irritable bowel syndrome]. Gastroenterol Hepatol 2004;27:325-43. (Pubitemid 38679838)
8. Schmulson M, Valenzuela J, Alvarado J et al. Consenso latinoamericano sobre el síndrome del intestino irritable: Algoritmode Diagnóstico y Tratamiento. [Latin-American consensus on irritable bowel syndrome: algorithm.] Gastroenterol Hepatol 2004;27:635. (Pubitemid 40039155)
9. Bernardes-Silva CF, Pereira AC, de Fatima Alves da Mota G, Krieger JE, Laudanna AA. Lactase persistence/non-persistence variants, C/T-13910 and G/A-22018, as a diagnostic tool for lactose intolerance in IBS patients. Clin Chim Acta 2007;386:7-11. (Pubitemid 47417955)
10. Choi YK, Kraft N, Zimmerman B, Jackson M, Rao SS. Fructose intolerance in IBS and utility of fructose-restricted diet. J Clin Gastroenterol 2008;42:233-8. (Pubitemid 351301486)
11. Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebocontrolled evidence. Clin Gastroenterol Hepatol 2008;6:765-71.
12. Park MI, Camilleri M. Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. Neurogastroenterol Motil 2006;18:595-607. (Pubitemid 44079763)
13. Atkinson W, Sheldon TA, Shaat N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomized controlled trial. Gut 2004;53:1459-64. (Pubitemid 39265266)
14. Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL. Metaanalysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:1253-69. (Pubitemid 40040072)
15. Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005;(2):CD003460.
16. Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005;100 (SUPPL. 1):S5-S21.
17. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome-a European perspective. Aliment Pharmacol Ther 2006;24:183-205. (Pubitemid 43972890)
18. Sun WM, Read NW, Verlinden M. Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol 1997;32:34-8. (Pubitemid 27026464)
19. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:499-510. (Pubitemid 24324487)
20. Nogueira JR, San-Román A, Jiménez SG, Cervantes AG. El aceite de menta como tratamiento sintomático para el síndrome de intestino irritable. Estudio prospectivo, abierto, a largo plazo. Rev Gastroenterol Méx 2004;69(Supl 3):317.
21. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136-47. (Pubitemid 30490414)
22. Schmulson M, Lopez-Alvarenga JC, Vargas J et al. Improvement in the IBSQOL scores of IBS-Rome III patients alter 4 weeks of treatment with oral pinaverium bromide 100 mg + simeticone 300 mg BID. A preliminary report of the Mexican IBS working group. Neurogastroenterol Motil 2008;20( SUPPL. 1):72 [abstract].
23. Schmulson M, Lopez-Alvarenga JC, Vargas J et al. Improvement in abdominal pain and stool consistency (Bristol scale) in IBS-Rome III patients alter 4 weeks of treatment with Pinaverium Bromide 100 mg + Simeticone 300 mg BID: a preliminary report of the Mexican IBS working group. Neurogastroenterol Motil 2008;20(SUPPL. 1):91 [abstract].
24. Barthet M, Mambrini P, Salducci J, Bouvier M, Chiarelli P, Grimaud JC. Efficacité de l'association citrate d'alverine-siméthicone dans le traitement du syndrome de l'intestin irritable. Act Med Int Gastroenterol 1996;10:S1-S7.
25. Manzano B, Hernández A, Herrera JA, Male R, Novoa G. Estudio de la eficacia y seguridad de la combinación del citrato de alverina y simeticona en el tratamiento del síndrome de intestino irritable en población mexicana. Pract Gastroenterol (Ed. Mex.): en prensa.
26. Camarri E. Fenoverine: smooth muscle synchronizer for the management of gastro-intestinal conditions. II. A trimebutine-controlled, double-blind, crossover clinical evaluation. Curr Med Res Opin 1986;10:52-7. (Pubitemid 16145080)
27. Jouglard J, Kozak-Ribbens G, de Haro L, Cozzone PJ. Research into individual predisposition to develop acute rhabdomyolysis attributed to fenoverine. Hum Exp Toxicol 1996;15:815-20. (Pubitemid 26372028)
28. Chen CW, Chang MH. Rhabdomyolysis induced by fenoverine: a case report and literature review. Acta Neurol Taiwan 2005;14:143-6.
29. Lembo T, Wright RA, Bagby B et al. Lotronex Investigator Team. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:2662-70.
30. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15:79-86. (Pubitemid 36313138)
31. Saad R, Chey WD. Recent developments in the treatments of the irritable bowel syndrome. Expert Opinion Invest Drugs 2008;17:117-30. (Pubitemid 351578195)
32. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A doseranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005;100:115-23. (Pubitemid 41623278)
33. Chey WD, Chey WY, Heath A et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004;99:2195-203. (Pubitemid 39524711)
34. Müller-Lissner, SA, Fumagalli I, Bardhan KD. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655-66. (Pubitemid 32912410)
35. Kellow J, Lee OY, Chang FY et al. An Asia-Pacific, double-blind, placebo -controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671-6. (Pubitemid 36528868)
36. Tougas G, Snape WJ Jr, Otten MH et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002;16:1701-8.
37. Thompson CA. Novartis suspends tegaserod sales at FDA's request. Am J Health Syst Pharm 2007;64:1020. (Pubitemid 46801527)
38. Comunicado a los Profesionales de la Salud. Tegaserod (Zelmac) 18 http//www.cofepris.gob.mx/bv/tegaserod.pdf
39. Seeger J, Loughlin J, Rivero E et al. No evidence for association of tegaserod with cardiovascular adverse ischemic events (CVIE) in routine clinical practice. Am J Gastroenterol 2008;103(SUPPL..1):S465 [abstract].
40. Schmulson M, Pulido-London D. Comorbilidad cardiovascular, Tegaserod y otros tratamientos en pacientes con Trastornos Funcionales Gastrointestinales (TFGI), Síndrome de Intestino Irritable (SII) y Estreñimiento Crónico (EC). Rev Gastroenterol Mex 2007;(Supl 2):180 [abstract].
41. Serra Pueyo J. [Intestinal gas and functional disorders of the gastrointestinal tract]. Gastroenterol Hepatol 2003;26:263-9. (Pubitemid 36569386)
42. Fardy J, Sullivan S. Gastrointestinal gas. CMAJ 1988;139:1137-42. (Pubitemid 19022339)
43. Azpiroz F, Serra J. Treatment of Excessive Intestinal Gas. Curr Treat Options Gastroenterol 2004;7:299-305. (Pubitemid 39139779)
44. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994;8:409-16. (Pubitemid 24257557)
45. Greenbaum DS, Mayle JE, Vanegeren LE et al. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 1987;32:257-66. (Pubitemid 17054266)
46. Drossman DA, Toner BB, Whitehead WE et al. Cognitive-behavioral therapy versus education and desimipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2004;125:249-53.
47. Abdul-Baki H, El Zahabi LMN, ElHajj II et al. A randomized double-blind placebo-controlled trial of imipramine in patients with irritable bowel syndrome. Am J Gastroenterol 2006;101:S479 [abstract].
48. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005;54:601-7. (Pubitemid 40559240)
49. Bahar RJ, Collins BS, Steinmetz B, Ament ME. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. J Pediatr 2008;152:685-9.
50. Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a doubleblind, placebo-controlled trial. Am J Gastroenterol 2004;99:914-20. (Pubitemid 39090223)
51. Masand PS, Gupta S, Schwartz TL et al. Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome? Psychosomatics (Pubitemid 35286052)
52. Creed F, Fernandes L, Guthrie E et al. North of England IBS Research Group. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124:303-17. (Pubitemid 36169247)
53. Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 2005;22:381-5. (Pubitemid 41248104)
54. Masand PS, Gupta S, Schwartz TL, Virk S, Hameed A, Kaplan DS. Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study. Prim Care Companion J Clin Psychiatry 2005;7:162-6. (Pubitemid 41783217)
55. Tack J, Broekaert D, Fischler B, Van Oudenhoven L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006;55:1095-103. (Pubitemid 44085674)
56. Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double- blind, randomized, placebo-controlled trial. Dig Dis Sci 2008;53:108-15. (Pubitemid 350265657)
57. Chial HJ, Camilleri M, Ferber I et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003;1:211-8. (Pubitemid 37248072)
58. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, ElHajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006;101:326-33. (Pubitemid 43381675)
59. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145:557-63. (Pubitemid 46780934)
60. Lembo A, Zakko SF, Ferreira NL et al. Rifaximin for the Treatment of Diarrhea- Associated Irritable Bowel Syndrome: Short Term Treatment Leading to Long Term Sustained Response. Gastroenterology 2008;134 (SUPPL. 1):A- 545 [abstract].
61. Ringel Y, Zakko SF, Ferreira NL, Bortey E, Wu T, Courtney K, Forbes WP, Lembo A, Pimentel M. Predictors of Clinical Response from a Phase 2 Multi- Center Efficacy Trial Using Rifaximin,a Gut-Selective, Nonabsorbes Antibiotic for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome. Gastroenterology 2008;134(SUPPL. 1):A-550 [abstract].
62. Pimentel M, Lin HC, Enayati P et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol 2006;290:G1089-95. (Pubitemid 43788289)
63. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007;52:139-42.
64. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:385-96. (Pubitemid 352033280)
65. Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 2008;103:958-63. (Pubitemid 351501116)
66. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14:2650-61.
67. Floch MH, Walker WA, Guandalini S et al. Recommendations for probiotic use. J Clin Gastroenterol 2008;42 (SUPPL. 2):S104-8.
68. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-96. (Pubitemid 351406304)
69. Chey WD, Drossman DA, Scott C, Panas RM, Ueno R. What Symptoms Drive Global Symptom Improvement with Lubiprostone in patients with irritable bowel syndrome and constipation: Data from two multicenter, randomized, placebo-controlled trials. Gastroenterology 2008;134(SUPPL. 1):A28 [abstract].
70. Chey WD, Drossman DA, Scott C, Panas RM, Ueno R. Lubiprostone is effective and well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and constipation. Gastroenterology 2008;134(SUPPL. 1):A-215 [abstract].
71. Chey WD, Saad RJ, Panas RM, Wahle A, Ueno R. Discontinuation of lubiprostone treatment for irritable bowel syndrome with constipation is not associated with symptoms increase or recurrence: results from a randomised withdrawal study. Gastroenterology 2008;134(SUPPL. I):A401 [abstract].
72. Lackner JM, Mesmer C, Morley S, Dowzer C, Hamilton S. Psychological treatments for irritable bowel syndrome: a systematic review and metaanalysis. J Consult Clin Psychol 2004;72:1100-13. (Pubitemid 39658543)
73. Whitehead WE. Hypnosis for irritable bowel syndrome: the empirical evidence of therapeutic effects. Int J Clin Exp Hypn 2006;54:7-20. (Pubitemid 41769751)
74. Wilson S, Maddison T, Roberts L, Greenfield S, Singh S; Birmingham; IBS Research Group. Systematic review: The effectiveness of hypnotherapy in the management of irritable bowel syndrome. Aliment Pharmacol Ther 2006;24:769-80.
75. Gholamrezaei A, Ardestani SK, Emami MH. Where does hypnotherapy stand in the management of irritable bowel syndrome? A systematic review. J Altern Complement Med 2006;12:517-27. (Pubitemid 44689674)
76. Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of Irritable Bowel Syndrome With Chinese Herbal Medicine: A Randomized Controlled Trial. JAMA 1998;280:1585-9. (Pubitemid 28520646)
77. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo- controlled, multi-centre trial. Aliment Pharmacol Ther 2004;19:271-9. (Pubitemid 38253501)
78. Liu J, Yang M, Liu Y, Wei M, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006;1:CD004116.
79. Lim B, Manheimer E, Lao L et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2006, Issue 4 No CD005111. DOI: 10.1002/14651858.CD005111.pub2 (Pubitemid 46841137)
80. Leventer SM, Raudibaugh K, Frissora CL et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008;27:197-206. (Pubitemid 350256611)
81. Mangel A. Asimadoline in the treatment of IBS [Abstract 682d]. Sesión de carteles presentada en DDW; 2008 mayo 17-22; San Diego, CA.
82. Lembo A. Linaclotide significantly improved bowel habits and relieved abdominal symptoms in adults with chronic constipation: Data from a larger four-week, randomized, double-blind, placebo-controlled study [Abstract 682f]. Sesión de carteles presentada en DDW; 2008 mayo 17-22; San Diego, CA.
83. Lembo AJ, Rosenbaum DP, Chey WD, Drossman DA. Safety and efficacy of crofelemer in patients with diarrhea-predominant irritable bowel syndrome (D-IBS). Gastroenterology 2007;132:A141.
84. Quigley EM, Devane J, Young D, Butler J. A randomized, double-blind, placebo- controlled study of R-verapamil in non-constipated irritable bowel syndrome. Am J Gastroenterol 2007;102(SUPPL. 2): S502 [abstract].